http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
배자와 태아에서 하악골의 형태발생 및 교원질 발현에 관한 면역조직화학적 연구
국윤아,김상철,김은철,김오환,김정기 대한치과교정학회 1996 대한치과교정학회지 Vol.26 No.2
치아 위치에 영향을 미치는 악안면의 성장 발육에서 Meckel 연골발생전 후의 하악골 형성과정과 교원 단백질 분포 및 발현정도를 알아보고자 좌고를 측정하여 태령을 결정한 후 4주부터 38주까지 50례의 배자와 태아를 대상으로 통법에 따른 조직절편을 제작하였으며 Hematoxylin과 Eosin, Alcian blue-pas와 Goldner의 Masson Trichrome 염색, 그리고 제1형과 제2형 교원 단백질에 대한 면역조직화학 염색을 시행하였다. 좌고 20.5 MM 배자에서 Meckel 연골이 출현하였으며, 좌고 22mm에서 38mm까지 하악골 외방에 신생골을 형성하고, 좌고 60mm태아에서 Meckel 연골이 점유하던 공간이 신생골로 채워져 연골내골화가 뚜렸하게 관찰되었으나, 좌고 240mm에서 Meckel 연골이 거의 소실되었다. 교원질에 대한 면역 염색결과에서 Mackel 연골 출현전 제1형 교원질 발현은 주로 상, 하악돌기의 구강상피에 국한되어 관찰되었고 제2형교원질 발현은 상대적으로 약간 적었다. Meckel 연골 출현 및 신생골 형성시기는 제1형교원질이 주로 치제상피와 신생골에서 약양성의 발현을 보였으며, Meckel 연골 및 신생골에서는 제1형보다 제2형의 교원질이 많이 발현되었다. 막내골화시기에는 제1형 교원질이 골아세포 및 골기질에서 중등도로 발현되었으나, 제2형에서는 경미하게 나타나 Meckel 연골형성전 후 제2형에서 제1형으로 발현전환이 있었다. Underlying malocclusions and dentofacial deformities are often related to variations in the craniofacial development. Type I and type Ⅱcollagens are considered the major collagens of bone and cartilage respectively. Monitoring the patterns of those protein expressions during development will provide a basis for the understanding of normal and abnormal growths. This study was undertaken to investigate the morphogenetic changes and the expression patterns of type I and Ⅱcollagen proteins involved in the developing mandible of human embryos and fetuses. 50 embryos and fetuses were studied with Hematoxylin and Eosin, Alcian blue-PAS, Masson Trichrome, and Immunohistochemical stains. The results were as follows: 1. A 13.5mm embryo showed the stomatodeum with dental lamina, maxillary and mandibular processes. Meckel's cartilage appeared in the mandibular arch of a 20.5mm embryo. New bone formation was bilaterally initiated at the outer side of middle portion of Meckel's cartilage of 22-38 mm embryos. 2. Meckel' cartilage was resorbed at the 15th week fetus. The endochondral ossification was observed where there was direct replacement of cartilage by bone. Meckel' cartilage disappeared and membraneous ossification were observed at the 25th week. 3. Before the appearance of Meckel's cartilage, the expression of type I collagen was moderate at the odontogenic epithelium of maxillary & mandibular process, but mild for the expression of type Ⅱ collagen. 4. During the appearance of Meckel's cartilage and new bone formation, the immunoactivity of type Ⅱ collagen was more expressed than type I collagen at the Meckel's cartilage and new bone. 5. During intramembranous bone formation, the expression of type Ⅱcollagen was rare in the bony trabeculae. There was a switch for the expression of collagens from type Ⅱto type I during the appearance of Meckel's cartilage.
( Kook Hwan Oh ),( Sung Kyun Kim ),( Eun Sook Nam ),( Ji Eun Oh ),( Soo Jin Kim ),( Se Won Oh ),( Ho Jun Chin ),( Ki Young Na ),( Dong Wan Chae ) 대한신장학회 2011 Kidney Research and Clinical Practice Vol.30 No.3
Purpose: AQP-1 (Aquaporin-1) and VEGF (vascular endothelial growth factor) are known to play an important role in ultrafiltration in peritoneal dialysis. The aim of this study was to evaluate the expression of AQP-1 and VEGF and VEGFR-1 (VEGF type 1 receptor) in peritoneums obtained from uremic non-dialyzed patients and peritoneal dialysis patients and to see if expression of these molecules are correlated with each other and with pathological findings in peritoneum. Methods: Peritoneal expressions of AQP-1, VEGF and VEGFR-1 were examined by immunohistochemistry using specific antibody to each molecule. The degree of vascular proliferation and inflammation in peritoneal tissues were assessed semi-quantitatively by a single pathologist. Results: AQP-1, VEGF and VEGFR-1 were mainly expressed in the vascular endothelial cells in the peritoneum. No significant difference in peritoneal expression of these molecules was found according to the clinical situations in which peritoneal tissues were obtained. The degree of expression of AQP-1 and VEGF were related to each other but not related to expression of VEGFR-1. The expressions of AQP-1 and VEGF were related to the vascular proliferation. The expression of AQP-1 was also related to inflammation. Conclusion: In end-stage renal disease patients before and after initiation of peritoneal dialysis, the peritoneal expressions of AQP-1 and VEGF were related to vascular proliferation. Inflammation might have some influence in expression of AQP-1.
The KNOW-CKD Study: What we have learned about chronic kidney diseases
( Kook-hwan Oh ),( Minjung Kang ),( Eunjeong Kang ),( Hyunjin Ryu ),( Seung Hyeok Han ),( Tae-hyun Yoo ),( Soo Wan Kim ),( Dong-wan Chae ),( Kyu-beck Lee ),( Sue K. Park ),( Yeong Hoon Kim ),( Curie A 대한신장학회 2020 Kidney Research and Clinical Practice Vol.39 No.2
As the nation’s largest chronic kidney disease (CKD) cohort, the KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease (KNOW-CKD) was established to investigate the clinical course, risk factors for progression, and adverse outcomes of CKD. From 2011 to 2016, the KNOW-CKD recruited 2,238 adult patients with CKD from stage G1 to G5 who were not receiving renal replacement therapy from nine tertiary care hospitals throughout Korea. As of 2019, the KNOW-CKD has published more than 50 articles in the areas of socio-economics, nutrition, quality of life, health-related habits, CKD progression, cardiovascular comorbidity and outcome, anemia, mineral bone disease, biomarker discovery, and international and inter-ethnic comparisons. The KNOW-CKD will eventually offer a prediction model for long-term consequences of CKD, such as the occurrences of end-stage renal disease, cardiovascular disease, and death, thereby enabling the identification and treatment of at-risk populations that require extra medical attention.
Oh, Kook-Hwan,Kim, Chiweon,Lee, Hankyu,Lee, Hajeong,Jung, Ji Yong,Kim, Nam Joong,Yu, Kyung-Sang,Shin, Kwang-Hee,Jang, In-Jin,Ahn, Curie American Society for Microbiology 2009 Antimicrobial Agents and Chemotherapy Vol.53 No.8
<B>ABSTRACT</B><P>The pharmacokinetic characteristics of piperacillin sodium were studied in five volunteers undergoing on-line hemodiafiltration (HDF). The subjects were given 2 g of piperacillin sodium intravenously over 1 min and placed on on-line HDF for 4 h starting at 60 min after the piperacillin infusion. Noncompartmental models were employed for estimation of the pharmacokinetic parameters, and intradialytic piperacillin clearance was calculated by the recovery method. The mean volume of distribution and the elimination half-life were 0.27 ± 0.13 liter/kg (mean ± standard deviation) and 1.1 ± 0.6 h, respectively. The total body clearance of piperacillin was 0.19 ± 0.08 liter/h/kg. Piperacillin clearance through on-line HDF was 0.11 ± 0.06 liter/h/kg. The mean serum piperacillin concentration was 4.0 ± 1.9 μg/ml at the end of the 4-h on-line HDF session. The concentration of infused piperacillin recovered in the dialysate was 527 ± 236 mg (26.3% ± 11.8%). We suggest the replacement of 500 mg of piperacillin after each on-line HDF session.</P>
Kook-Hwan Oh,Sue K. Park,Jayoun Kim,Curie Ahn 대한예방의학회 2022 예방의학회지 Vol.55 No.4
The KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease (KNOW-CKD) was launched in 2011 with the support of the Korea Disease Control and Prevention Agency. The study was designed with the aim of exploring the various clinical features and characteristics of chronic kidney disease (CKD) in Koreans, and elucidating the risk factors for CKD progression and adverse outcomes of CKD. For the cohort study, nephrologists at 9 tertiary university-affiliated hospitals participated in patient recruitment and follow-up. Biostatisticians and epidemiologists also participated in the basic design and structuring of the study. From 2011 until 2016, the KNOW-CKD Phase I recruited 2238 adult patients with CKD from stages G1 to G5, who were not receiving renal replacement therapy. The KNOW-CKD Phase II recruitment was started in 2019, with an enrollment target of 1500 subjects, focused on diabetic nephropathy and hypertensive kidney diseases in patients with reduced kidney function who are presumed to be at a higher risk of adverse outcomes. As of 2021, the KNOW-CKD investigators have published articles in the fields of socioeconomics, quality of life, nutrition, physical activity, renal progression, cardiovascular disease and outcomes, anemia, mineral bone disease, serum and urine biomarkers, and international and inter-ethnic comparisons. The KNOW-CKD researchers will elaborate a prediction model for various outcomes of CKD such as the development of end-stage kidney disease, major adverse cardiovascular events, and death.
Oh, Sung Woo,Myung, Seung‐,Taek,Oh, Seung‐,Min,Oh, Kyu Hwan,Amine, Khalil,Scrosati, Bruno,Sun, Yang‐,Kook WILEY‐VCH Verlag 2010 Advanced Materials Vol.22 No.43
<P><B>Micrometer‐size LiFePO<SUB>4</SUB> spheres</B> with homogeneous double carbon coating layers have been prepared as potential electrode materials for battery applications. The double carbon‐coated LiFePO<SUB>4</SUB> electrodes in a lithium‐ion cell exhibited discharge capacities of the order of 160 mAh g<SUP>−1</SUP> and 115 mAh g<SUP>−1</SUP> at 25 °C under 0.1 C‐rate and 10 C‐rate, respectively. </P>
Outcome of Early Initiation of Peritoneal Dialysis in Patients with End-Stage Renal Failure
Oh, Kook-Hwan,Hwang, Young-Hwan,Cho, Jung-Hwa,Kim, Mira,Ju, Kyung Don,Joo, Kwon Wook,Kim, Dong Ki,Kim, Yon Su,Ahn, Curie,Oh, Yun Kyu The Korean Academy of Medical Sciences 2012 JOURNAL OF KOREAN MEDICAL SCIENCE Vol.27 No.2
<P>Recent studies reported that early initiation of hemodialysis may increase mortality. However, studies that assessed the influence of early initiation of peritoneal dialysis (PD) yielded controversial results. In the present study, we evaluated the prognosis of early initiation of PD on the various outcomes of end stage renal failure patients by using propensity-score matching methods. Incident PD patients (n = 491) who started PD at SNU Hospital were enrolled. The patients were divided into 'early starters (n = 244)' and 'late starters (n = 247)' on the basis of the estimated glomerular filtration rate (eGFR) at the start of dialysis. The calculated propensity-score was used for one-to-one matching. After propensity-score-based matching (n = 136, for each group), no significant differences were observed in terms of all-cause mortality (<I>P</I> = 0.17), technique failure (<I>P</I> = 0.62), cardiovascular event (<I>P</I> = 0.96) and composite event (<I>P</I> = 0.86) between the early and late starters. Stratification analysis in the propensity-score quartiles (n = 491) exhibited no trend toward better or poorer survival in terms of all-cause mortality. In conclusion, early commencement of PD does not reduce the mortality risk and other outcomes. Although the recent guidelines suggest that initiation of dialysis at higher eGFR, physicians should not determine the time to initiate PD therapy simply rely on the eGFR alone.</P>